US › Healthcare

Adicet Bio Inc (ACET)

US · Healthcare · Biotechnology

$4.57-11.09%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-21.4M

EPS

$-1.99

EPS estimate

$-2.43

EPS came in at -1.99 against a street estimate of -2.43 — a beat of 18.1%.

Key statistics

Market cap

$47.8M

Forward P/E

0.0

P/B

0.66

Book value

$11.16

EPS (TTM)

$-10.42

52-week high

$17.04

52-week low

$4.80

50-day MA

$8.37

200-day MA

$7.96

Beta

1.63

Analyst view

Analysts rate Adicet Bio Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $34.83.

Shareholding

Insiders

1.08%

Institutions

64.72%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	9.96%
Orbimed Advisors LLC	9.02%
Franklin Templeton Inc	6.69%
Citadel Advisors Llc	4.62%
Vanguard Capital Management, LLC	3.67%
Adage Capital Partners Gp LLC	2.93%
Renaissance Technologies Corp	2.84%
Stonepine Capital Management Llc	2.62%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adicet Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.